stoxline Quote Chart Rank Option Currency Glossary
  
Inozyme Pharma, Inc. (INZY)
1.29  -0.11 (-7.86%)    02-11 16:00
Open: 1.4
High: 1.42
Volume: 712,961
  
Pre. Close: 1.4
Low: 1.27
Market Cap: 83(M)
Technical analysis
2025-02-11 4:46:37 PM
Short term     
Mid term     
Targets 6-month :  2.78 1-year :  3.6
Resists First :  2.38 Second :  3.08
Pivot price 1.4
Supports First :  1.23 Second :  1.02
MAs MA(5) :  1.43 MA(20) :  1.4
MA(100) :  3.38 MA(250) :  4.48
MACD MACD :  -0.3 Signal :  -0.4
%K %D K(14,3) :  38.1 D(3) :  53.9
RSI RSI(14): 30.9
52-week High :  7.79 Low :  1.23
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ INZY ] has closed above bottom band by 8.9%. Bollinger Bands are 75.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.42 - 1.43 1.43 - 1.44
Low: 1.25 - 1.26 1.26 - 1.27
Close: 1.27 - 1.29 1.29 - 1.3
Company Description

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Headline News

Fri, 07 Feb 2025
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

Sun, 19 Jan 2025
Inozyme Pharma, Inc. (NASDAQ:INZY) Short Interest Update - MarketBeat

Fri, 10 Jan 2025
Inozyme reports promising data on rare disease treatments - Investing.com

Fri, 10 Jan 2025
Inozyme Pharma stock hits 52-week low at $2.37 amid market challenges - Investing.com

Fri, 10 Jan 2025
Inozyme Pharma Announces Positive Interim Data for INZ-701 - GlobeNewswire

Sun, 17 Nov 2024
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet? - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 64 (M)
Shares Float 37 (M)
Held by Insiders 0.5 (%)
Held by Institutions 98.9 (%)
Shares Short 3,850 (K)
Shares Short P.Month 3,320 (K)
Stock Financials
EPS -1.55
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.28
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -35.7 %
Return on Equity (ttm) -79.5 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.54
Qtrly Earnings Growth 0 %
Operating Cash Flow -91 (M)
Levered Free Cash Flow -56 (M)
Stock Valuations
PE Ratio -0.84
PEG Ratio 0
Price to Book value 1
Price to Sales 0
Price to Cash Flow -0.91
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android